SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Ladiratuzumab vedotin

Cat. No.: HY-P99683

CAS No.: 1629760-29-7

Target: Antibody-Drug Conjugates (ADCs)

Pathway: Antibody-drug Conjugate/ADC Related

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC_{50}: 5.6 nM for LIV-1).
Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker.
Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer[1][2][3][4].

In Vitro

Ladiratuzumab vedotin (LIV-1+ cells) activates the ER stress response via the activation of ATF6 and phosphorylation of IRE1 and eIF2a[3].
Ladiratuzumab vedotin (LIV-1+ cells) releases ATP and HMGB1 into the supernatant (hallmarks of ICD[3].
Ladiratuzumab vedotin (0-100 ng/mL) shows cytotoxic activity against MCF-7 cell line[4].
Ladiratuzumab vedotin (1 μg/mL, 24 h) internalizes, traffics to the lysosome, and disrupts the microtubule network in MCF-7 cells[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line:	MCF-7
Concentration:	0-100 ng/mL
Incubation Time:	96 h
Result:	Inhibited cell viability with an EC_{50} value of 6.3 ng/mL.

In Vivo

Ladiratuzumab vedotin (3 mg/kg, i.p., every 4 days) results tumor regression in MCF-7 breast cancer cell xenograft model[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MCF-7 breast cancer cell xenograft model[4]
Dosage:	3 mg/kg
Administration:	i.p., every 4 days
Result:	Delayed tumor growth.

Animal Model:	BALB/C mice (PK assay)[4]
Dosage:	3 mg/kg
Administration:	i.v., single
Result:	Showed a terminal half-life of 6.8 days.

REFERENCES

[1]. Rizzo A, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498.

[2]. Jane Lowe Meisel, et al. Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Journal of Clinical Oncology. 2022 40:16_suppl, TPS1127-TPS1127.

[3]. Anthony T. Cao, et al. Abstract 2742: Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Res (2018) 78 (13_Supplement): 2742.

[4]. Sussman D, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA